Filing Details
MADRIGAL PHARMACEUTICALS, INC. (NASDAQ:MDGL) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on July 30, 2026.
The Healthcare company reported Q0 revenue of .
10q filedNASDAQ:MDGL
MADRIGAL PHARMACEUTICALS, INC. (MDGL) Files Quarterly Report for Q0
Filing Details MADRIGAL PHARMACEUTICALS, INC. (NASDAQ:MDGL) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on July 30, 2026. The Healthcare…
Market Context
MADRIGAL PHARMACEUTICALS, INC.'s stock currently trades at $493.11 with a market capitalization of $12.7B.
The 10-Q provides MADRIGAL PHARMACEUTICALS, INC.'s quarterly financial update, including unaudited financial statements and management commentary on recent performance. While less detailed than the annual 10-K, the 10-Q often contains timely information about emerging trends, updated risk factors, and changes in business conditions since the last filing.
All SEC filings for MADRIGAL PHARMACEUTICALS, INC. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View MDGL Stock Page
Frequently Asked Questions
Where can I read MDGL's SEC filings?
Browse all filings on our MDGL SEC filings page.
What types of SEC filings does MADRIGAL PHARMACEUTICALS, INC. file?
Public companies like MADRIGAL PHARMACEUTICALS, INC. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.